Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Sep;29(3):232-8.
doi: 10.1055/s-0036-1584292.

The Multidisciplinary Management of Colorectal Cancer: Present and Future Paradigms

Chelsie K Sievers  1 , Jeremy D Kratz  2 , Luke D Zurbriggen  2 , Noelle K LoConte  3 , Sam J Lubner  3 , Natalya Uboha  3 , Daniel Mulkerin  3 , Kristina A Matkowskyj  4 , Dustin A Deming  5
Affiliations
Review

The Multidisciplinary Management of Colorectal Cancer: Present and Future Paradigms

Chelsie K Sievers et al. Clin Colon Rectal Surg. 2016 Sep.

Abstract

As treatment strategies for patients with colorectal cancer advance, there has now become an ever-increasing need for multidisciplinary teams to care for these patients. Recent investigations into the timing and duration of perioperative therapy, as well as, the rise of molecular profiling have led to more systemic chemotherapeutic options. The most efficacious use, in terms of timing and patient selection, of these therapies in the setting of modern operative and radiotherapy techniques requires the generation of care teams discussing cases at multidisciplinary conferences. This review highlights the role of multidisciplinary team conferences, advances in perioperative chemotherapy, current clinical biomarkers, and emerging therapeutic agents for molecular subtypes of metastatic colon cancer. As our understanding of relevant molecular subtypes increases and as data becomes available on treatment response, the treatment of colorectal cancer will become more precise and effective.

Keywords: chemotherapy; colon cancer; rectal cancer.

PubMed Disclaimer

Conflict of interest statement

Funding This project was supported by the National Institutes of Health P30 CA014520 (Core Grant, University of Wisconsin Carbone Cancer Center, Madison, WI).

References

    1. American Cancer Society . Atlanta, GA: American Cancer Society; 2016. Cancer Facts & Figures 2016.
    1. Glimelius B, Dahl O, Cedermark B. et al.Adjuvant chemotherapy in colorectal cancer: a joint analysis of randomised trials by the Nordic gastrointestinal tumour adjuvant therapy group. Acta Oncol. 2005;44(8):904–912. - PubMed
    1. Fuchs C S, Marshall J, Mitchell E. et al.Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol. 2007;25(30):4779–4786. - PubMed
    1. de Gramont A, Figer A, Seymour M. et al.Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18(16):2938–2947. - PubMed
    1. Venook A P Niedzwiecki D Lenz H J et al.CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum J Clin Oncol 2014. (Supplemental Abstract LBA3)